

July 28, 2026

The Manager- Listing
BSE Limited
P J Towers, Dalal Street, Fort,
Mumbai – 400 001

The Manager- Listing
National Stock Exchange of India Limited
Exchange Plaza,
Bandra – Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Company has received a demand notice issued by the National Pharmaceutical Pricing Authority (NPPA) for alleged overcharging under the Drugs (Prices Control) Order, 2013 (DPCO, 2013). The Company is currently reviewing the demand notice and will take appropriate steps in accordance with applicable law.

In this regard, please find the details as required under the SEBI Circular HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 attached herewith as **Annexure – A**.

Kindly take the above information on record.

Thanking You,
For AstraZeneca Pharma India Limited

Tanya Sanish
Company Secretary & Compliance Officer

Annexure – A

Sl. No.	Particulars	Details
1.	Name of the authority	National Pharmaceutical Pricing Authority (NPPA)
2.	Nature and details of the action(s)	Demand Notice issued by the NPPA for alleged overcharging under the Drugs (Prices Control) Order, 2013 ('DPCO, 2013') of Rs. 79,97,457/- inclusive of interest calculated upto August 10, 2026.
3.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	July 27, 2026
4.	Details of the violation(s)/contravention(s) committed or alleged to be committed	NPPA has alleged that AstraZeneca Pharma India Ltd. sold/ marketed Betaloc-50 (Metoprolol 50 mg tablets) at an MRP higher than the ceiling price notified under DPCO, 2013, and has not implemented the revised ceiling price on stocks available in the market from the notifications i.e. Notification S.O. 644(E) dated 02.03.2016 and Notification S.O. 1352(E) dated 02.06.2016 in respect of Betaloc-50 tablets. This has allegedly resulted in overcharging during the period of June to July 2016, for which NPPA has demanded recovery of the overcharged amount along with applicable interest to be paid within 30 days from the date of receipt of the Notice.
5.	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible	Demand of Rs. 79,97,457/- inclusive of interest calculated upto August 10, 2026.